Poop pills and immunotherapy: a new hope for lung cancer?
NCT ID NCT05669846
First seen Mar 11, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This study is testing whether a fecal transplant from a healthy donor, combined with the immunotherapy drug pembrolizumab, can help people with a certain type of advanced lung cancer (PD-L1 positive non-small cell lung cancer) that has not responded to previous treatments. The transplant is given via colonoscopy or capsules to restore healthy gut bacteria, which may boost the immune system's ability to fight cancer. The trial will enroll 26 participants and measure tumor shrinkage and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Healthy donor fecal microbiota transplant (FMT) and pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase study with only 26 participants, so results may not apply to everyone. The combination therapy may cause side effects like immune-related reactions or infections from the transplant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.